Hyperfine, Inc.
$1.29
▲
3.67%
2026-04-21 07:25:00
www.hyperfinemri.com
NGM: HYPR
Explore Hyperfine, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$128.32 M
Current Price
$1.29
52W High / Low
$2.22 / $0.53
Stock P/E
—
Book Value
$0.42
Dividend Yield
—
ROCE
-85.19%
ROE
-79.01%
Face Value
—
EPS
$-0.43
Exp Qtr EPS
—
Sector
Healthcare
Industry
Medical Devices
Employees
102
Beta
1.06
Debt / Equity
0.77
Current Ratio
4.34
Quick Ratio
3.73
Forward P/E
-3.67
Price / Sales
8.79
Enterprise Value
$83.76 M
EV / EBITDA
-2.33
EV / Revenue
6.17
Rating
None
Target Price
$2.05
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Treace Medical Concepts, Inc. | $1.97 | — | $125.31 M | — | -33.86% | -58.94% | $7.78 / $1.17 | $1.37 |
| 2. | Boston Scientific Corporation | $65.03 | 33.52 | $96.13 B | 0% | 10.39% | 12.45% | $109.5 / $60.59 | $16.34 |
| 3. | Baird Medical Investment Holdings Limited | $1.79 | 55.75 | $64.64 M | — | 35.34% | -8.03% | $7.26 / $0.76 | $1.34 |
| 4. | NovoCure Limited | $12.67 | — | $1.44 B | — | -26.47% | -38.89% | $20.06 / $9.82 | $3.03 |
| 5. | Globus Medical, Inc. | $96.1 | 24.49 | $13.01 B | — | 11.18% | 12.29% | $101.4 / $51.79 | $33.86 |
| 6. | Enovis Corporation | $26.27 | — | $1.52 B | — | -0.58% | -58.27% | $37.85 / $21 | $26.05 |
| 7. | iTonic Holdings Ltd. | $0.32 | — | $5.41 M | — | -59.82% | -71.25% | $32 / $0.25 | $0.36 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | |
|---|---|---|---|---|---|
| Sales | 5.29 M | 3.44 M | 2.7 M | 2.14 M | 2.32 M |
| Operating Profit | -7.67 M | -8.92 M | -9.6 M | -10.9 M | -10.77 M |
| Net Profit | -5.91 M | -11.02 M | -9.22 M | -9.42 M | -10.39 M |
| EPS in Rs | -0.07 | -0.13 | -0.11 | -0.11 | -0.12 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 13.56 M | 12.89 M | 11.03 M | 6.81 M |
| Operating Profit | -37.09 M | -43.22 M | -48.12 M | -73.87 M |
| Net Profit | -35.57 M | -40.72 M | -44.24 M | -73.16 M |
| EPS in Rs | -0.43 | -0.49 | -0.53 | -0.88 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 55.26 M | 58.9 M | 94.2 M | 134.05 M |
| Total Liabilities | 14.26 M | 9.86 M | 9.8 M | 10.33 M |
| Equity | 41.01 M | 49.04 M | 84.4 M | 123.72 M |
| Current Assets | 50.91 M | 53.71 M | 88.91 M | 128.66 M |
| Current Liabilities | 11.73 M | 8.73 M | 8.77 M | 8.8 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -27.95 M | -38.77 M | -41.81 M | -72.34 M |
| Investing CF | -1.19 M | -0.38 M | -0.8 M | -0.58 M |
| Financing CF | 27.5 M | 1.02 M | 0.17 M | 0.01 M |
| Free CF | -29.13 M | -39.15 M | -42.61 M | -72.92 M |
| Capex | -1.19 M | -0.38 M | -0.8 M | -0.58 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 16.84% | 61.9% | — | — |
| Earnings Growth % | 7.95% | 39.54% | — | — |
| Profit Margin % | -315.9% | -401% | -1073.73% | — |
| Operating Margin % | -335.33% | -436.14% | -1084.15% | — |
| Gross Margin % | 45.7% | 43.12% | 13.31% | — |
| EBITDA Margin % | -327.5% | -426.59% | -1069.25% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.